Coherus BioSciences, Inc. presented interim data from its Phase 1 clinical trial evaluating CHS-114, a selective, cytolytic anti-CCR8 antibody, at the 2025 American Association for Cancer Research (AACR) Annual Meeting. The data focused on CHS-114 as monotherapy and in combination with toripalimab in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).
The results showed a confirmed partial response in a heavily pretreated patient who was refractory to prior PD-1 inhibition. Furthermore, the study demonstrated greater than 50% depletion of CCR8+ regulatory T cells (Tregs) in paired tumor biopsies, accompanied by a marked increase in tumor-infiltrating CD8+ T cells, providing clear proof of mechanism.
The safety profile of CHS-114 was consistent with advanced disease and the known safety profile of toripalimab, supporting its continued evaluation in combination therapies. Coherus is actively enrolling an additional 40 HNSCC patients in an earlier, second-line setting, with efficacy and safety data expected in the first half of 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.